top of page
Vet Examining Dog

Canine Oncology Treatment Data

Intratumoral (IT) administration of MIE-201 has demonstrated durable and systemic antitumor activity as a single agent and in combination treatment regimens in studies of canine patients with several different cancers.

Antitumor Activity Observed in Naturally Occurring Canine Cancers

>25 dogs treated to date

Single Agent     

  • Mammary cancer (MC) (unpublished)

  • Inflammatory mammary cancer (IMC)

Combination Treatment

  • Melanoma with radiation

  • IMC with chemotherapy

  • Carcinoma with radiation + hyperthermia

Overall Observations

• Single agent anti-tumor activity

• Combination treatment activity

• Increased recruitment of immune cells into tumors

• Systemic anti-tumor responses (abscopal effect observed)

• Positive safety profile

Canine Data: Broad and Consistent Immune Activation and Antitumor Effects

If you are a veterinarian interested in learning more about MIE-201 and our plans for its continued development for the treatment of canine cancers, please  contact us.

    bottom of page